ArticleOncogene2002
The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- The transcription factor complex LMO2/TAL1 regulates branching and endothelial cell migration in sprouting angiogenesis.Scientific reports · 2022Article
- Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2.Oncotarget · 2020Article
- Hematopoietic Stem Cell Transcription Factors in Cardiovascular Pathology.Frontiers in genetics · 2020Review
- Network analysis of DEGs and verification experiments reveal the notable roles of PTTG1 and MMP9 in lung cancer.Oncology letters · 2018Article
- Hybrid Method Based on Information Gain and Support Vector Machine for Gene Selection in Cancer Classification.Genomics, proteomics & bioinformatics · 2017Article
- LMO2 (LIM Domain Only 2) and Endothelial Cell Migration in Developmental and Postnatal Angiogenesis.Arteriosclerosis, thrombosis, and vascular biology · 2017Article
- LIM Domain Only 2 Regulates Endothelial Proliferation, Angiogenesis, and Tissue Regeneration.Journal of the American Heart Association · 2016Article
- Identification of potential therapeutic targets for lung cancer by bioinformatics analysis.Molecular medicine reports · 2016Article
- Article
- LMO2 at 25 years: a paradigm of chromosomal translocation proteins.Open biology · 2015Review
- GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2.Angiogenesis · 2013Article
- LIM-domain-only proteins in cancer.Nature reviews. Cancer · 2013Review
- Solution structure of a tethered Lmo2(LIM2) /Ldb1(LID) complex.Protein science : a publication of the Protein Society · 2012Article
- Article
- Angiopoietin-2 is a direct transcriptional target of TAL1, LYL1 and LMO2 in endothelial cells.PloS one · 2012Article
- The regulatory epicenter of miRNAs.Journal of biosciences · 2011Article
- The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.American journal of clinical pathology · 2009Article
- Molecular alterations in primary prostate cancer after androgen ablation therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2005Article
- Null mutation of the Lmo4 gene or a combined null mutation of the Lmo1/Lmo3 genes causes perinatal lethality, and Lmo4 controls neural tube development in mice.Molecular and cellular biology · 2004Article
- Structural basis for the recognition of ldb1 by the N-terminal LIM domains of LMO2 and LMO4.The EMBO journal · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growth of solid tumours requires a blood supply provided by re-modeling of existing blood vessel endothelium (angiogenesis). Little is known about transcription regulators which are specific for the control of tumour angiogenesis. The proto-oncogene LMO2 encodes a LIM domain transcription regulator which controls angiogenesis during mouse embryogenesis where it regulates remodelling of the capillary network into mature vessels. We now show that Lmo2 expression is augmented in tumour endothelium such as mouse thymomas and human lung tumours. The functional significance of this Lmo2 expression was assessed in teratocarcinomas induced in nude mice by subcutaneous implantation of Lmo2-lacZ targeted ES cells. CD31-positive, sprouting endothelium of ES-cell origin occurred in teratocarcinomas from heterozygous Lmo2-lacZ ES cells but none occurred from null Lmo2-lacZ ES cells. Therefore, in this model Lmo2 is an obligatory regulator of neo-vascularization of tumours. These data suggest that LMO2 function may be a drug target in cancer and other conditions characterized by neo-vascularization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.